Trial Profile
A Randomized Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 15 May 2012 Actual patient number changed from 74 to 76 as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2011 Results for full six-month treatment analysis expected in the second quarter of 2011, according to a XOMA media release.